https://scholars.lib.ntu.edu.tw/handle/123456789/202422
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor | 檢驗醫學科 | en |
dc.contributor.author | CHANG, GEE-CHEN | en |
dc.contributor.author | LIU, KO-JIUNN | en |
dc.contributor.author | HSIEH, CHIA-LING | en |
dc.contributor.author | LUH, KWEN-TAY | en |
dc.contributor.author | HSU, LI-HAN | en |
dc.contributor.author | CHEN, CHIH-YI | en |
dc.contributor.author | CHEN, KUN-CHIEH | en |
dc.contributor.author | YANG, TSUNG-YING | en |
dc.contributor.author | CHOU, TEH-YI | en |
dc.contributor.author | WHANG-PENG, JACQUELINE | en |
dc.contributor.author | SHIH, NENG-YAO | en |
dc.creator | 張基晟;劉柯俊;謝嘉玲;陸坤泰;許立翰;陳姿怡;陳焜結;楊宗穎;周德盈;彭汪嘉康 | zh-tw |
dc.creator | CHANG, GEE-CHEN;LIU, KO-JIUNN;HSIEH, CHIA-LING;LUH, KWEN-TAY;HSU, LI-HAN;CHEN, CHIH-YI;CHEN, KUN-CHIEH;YANG, TSUNG-YING;CHOU, TEH-YI;WHANG-PENG, JACQUELINE;SHIH, NENG-YAO | en |
dc.date | 2006 | en |
dc.date.accessioned | 2009-09-25T01:25:51Z | - |
dc.date.accessioned | 2018-07-12T09:25:11Z | - |
dc.date.available | 2009-09-25T01:25:51Z | - |
dc.date.available | 2018-07-12T09:25:11Z | - |
dc.date.issued | 2006 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/94630 | - |
dc.description.abstract | Purpose: Although existence of humoral immunity has been previously shown in malignant pleural effusions, only a limited number of immunogenic tumor-associated antigens (TAA ) have been identified and associated with lung cancer. In this study, we intended to identify more TAAs in pleural effusion-derived tumor cells. Experimental Design: Using morphologically normal lung tissues as a control lysate in Western blotting analyses, 54 tumor samples were screened with autologous effusion antibodies. Biochemical purification and mass spectrometric identification of TAAs were done using established effusion tumor cell lines as antigen sources. We identified a p48 antigen as of-enolase ( ENO1). Semiquantitative immunohistochemistry was used to evaluate expression status of ENO1 in the tissue samples of 80 patients with non-small cell lung cancer (NSCLC) and then correlated with clinical variables. Results: Using ENO1- specifc antiserum, up-regulation of ENO1 expression in effusion tumor cells from 11 of 17 patients was clearly observed compared with human normal lung primary epithelial and non-cancer-associated effusion cells. Immunohistochemical studies consistently showed high level of ENO1 expression in all the tumors we have examined thus far. Log-rank and Cox's analyses of ENO1 expression status revealed that its expression level in primary tumors was a key factor contributing to overall- and progression- free survivals of patients (P < 0.05). The same result was also obtained in the early stage of NSCLC patients, showing that tumors expressing relatively higher ENO1 level were tightly correlated with poorer survival outcomes. Conclusions: Our data strongly support a prognostic role of ENO1 in determining tumor malignancy of patients with NSCLC. | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | CLINICAL CANCER RESEARCH v.12 n.19 pp.5746-5754 | en |
dc.relation.ispartof | CLINICAL CANCER RESEARCH | - |
dc.subject | HYPOXIA-INDUCIBLE FACTOR-1 | en |
dc.subject | CELL-LINES | en |
dc.subject | PROTEOMIC ANALYSIS | en |
dc.subject | TUMOR PROGRESSION | en |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | Identification of Alpha-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes | en |
dc.relation.pages | 5746-5754 | - |
dc.relation.journalvolume | v.12 | - |
dc.relation.journalissue | n.19 | - |
item.languageiso639-1 | en_US | - |
item.grantfulltext | none | - |
item.fulltext | no fulltext | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。